Most nootropic claims involve a compound doing something to the brain directly. In cells and animals, lion's mane's most interesting compounds raise the brain's own nerve growth factor. Whether that happens in people, and whether it matters, hasn't been shown.
Disclosure. I rarely recommend mushroom supplements. If I do, it’s usually brands such as Hifas da Terra or MediHerb through Amrita Nutrition; if you buy through my practitioner link I earn commission. You’re free to buy anywhere.
Following July's reishi profile, this month's fungi entry is Hericium erinaceus — lion's mane, named for the cascading white spines that make it look nothing like a typical mushroom. It's had genuine culinary and medicinal use across East Asia for centuries, but the reason it's become one of the more talked-about compounds in cognitive health circles is a specific, unusual mechanism.
Lion's mane contains two distinct classes of active compound depending on which part of the fungus you're using. Hericenones come from the fruiting body — the visible mushroom. Erinacines come from the mycelium — the root-like network the fungus grows through its substrate. This matters clinically, because many cheaper products use mycelium grown on grain, which can add starch from the grain. The distinction between fruiting-body and mycelium-based extracts is one of the single biggest quality variables in this entire category.
Nerve growth factor (NGF) is a protein essential for the survival, maintenance and growth of neurons — a deficiency in NGF signalling is implicated in the pathology of neurodegenerative conditions including Alzheimer's disease. The problem is that NGF itself is a large protein molecule that can't cross the blood-brain barrier if given directly, which is why supplementing NGF itself has never been a viable therapeutic route.
In cell and animal studies, hericenones and erinacines appear to work differently: they are small molecules, some of which reach the brain in animals, where they raise the brain's own NGF production. None of this has been measured in the human brain. Erinacines in particular appear to have the stronger effect and better penetration. In preclinical work using amyloid-beta-injected mice and transgenic Alzheimer's models, erinacine-A-enriched extracts reduced amyloid plaque deposition and improved learning and memory measures.
This is the honest part. The cell and animal evidence for NGF stimulation is consistent, but it is mechanistic: it shows a pathway, not a benefit in people. The human clinical evidence is real but thin: trials have been small, generally short in duration, and results across cognition studies have been described even by neutral reviewers (including the Alzheimer's Drug Discovery Foundation) as mixed.
The most cited human trial — Mori and colleagues, 2009 — randomised 30 Japanese adults aged 50 to 80 with mild cognitive impairment to dried fruiting-body tablets or placebo for 16 weeks. Scores on a cognitive scale (the revised Hasegawa Dementia Scale) were significantly better than placebo at weeks 8, 12 and 16, then fell significantly within four weeks of stopping — suggesting an effect that needs ongoing use rather than a lasting change from a short course. The trial was small, and its lead author worked for Hokuto Corporation, a mushroom producer (Mori et al., Phytotherapy Research 2009, doi:10.1002/ptr.2634).
Since then, a handful of other trials have been published. All are small; several are single-dose studies; and three have links to companies that make or test supplements.
Memory in older adults with early decline: mixed. Small trials, two of them company-run, with benefit seen only while people were taking it.
Memory and thinking in healthy younger adults: mostly null. A few single results in small studies, no consistent effect.
Brain fog, focus, ADHD: none. No human trials. That isn’t proof it does nothing; it just hasn’t been tested for what it’s most often sold for.
Older-adult trials: the Mori and Saitsu trials used dried fruiting-body tablets, with effects in Mori appearing from week 8 of 16 — not a same-day effect. The Alzheimer’s pilot used a mycelium product. Products vary a lot, so what’s in a capsule may bear little relation to what was tested.
Form matters here more than almost anywhere else in this series: look specifically for fruiting-body-derived extract (for hericenones) or a dual extraction covering mycelium (for erinacines), rather than "mycelium on grain" products, which can contain a lot of grain starch.
Lion's mane doesn't have a direct biomarker "confirmation" the way a nutrient deficiency does — there's no blood test for NGF status. No trial has tested lion’s mane for brain fog, word-finding difficulty or mental fatigue, so the grade there is none. Brain fog is a symptom, not a diagnosis: sleep, iron, thyroid, blood sugar, B12 and folate, homocysteine, inflammation, medications, low mood and stress can all cause it, and most of those can be tested. That’s where to start, rather than reaching for a mushroom first.
The most honest framing: this is a compound with an elegant mechanism, well documented in cells and animals, and human evidence that hasn't yet caught up to how interesting the mechanism is. Both things are true at once.
Skip it if you’re allergic to mushrooms. Talk to your GP first if you’re pregnant or breastfeeding, or take blood thinners or diabetes medicine; that last point is precautionary and rests on animal and lab data only, not on known interactions in people.
If someone's cognitive symptoms are new, worsening, or accompanied by other neurological signs, that's a reason for proper medical investigation, not a reason to start a mushroom extract and wait. Lion's mane sits appropriately as an adjunct once the more foundational and better-evidenced pieces of a cognitive picture have already been addressed.
Ask AIdan what a cognitive-support protocol should actually prioritise given your test results.
Ask AIdan → See the TDG Programme